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Abstract
Introduction Single-nucleotide polymorphisms (SNPs) in
codon 72 of the TP53 (also known as p53) gene (rs1042522)
and in the promoter region of the MDM2  gene (SNP309;
rs2279744) have been suggested to play roles in many
cancers. We investigated whether these SNPs were associated
with patient outcome and the effect of adjuvant systemic
therapy.
Methods The genotypes of TP53  codon 72 and MDM2
SNP309 were defined among 557 primary Japanese breast
cancer patients (median follow-up, 61.7 months). The effects of
several variables on survival were tested by Cox's proportional
hazards regression analysis.
Results We showed that the Pro/Pro genotype of TP53 codon
72 was associated with poorer disease-free survival (DFS) than
other genotypes by Kaplan-Meier analysis (P  = 0.049) and
multivariate Cox's proportional hazards regression analysis (P =
0.047, risk ratio of recurrence = 1.67), whereas MDM2
SNP309 status was not associated with DFS. The association
of the Pro/Pro TP53 genotype with poorer DFS was especially
significant in patients who received adjuvant chemotherapy (P =
0.009). In contrast, among the patients who had received
adjuvant hormonal therapy or no adjuvant systemic therapy,
TP53 codon 72 genotype was not associated with DFS.
Conclusion The Pro/Pro genotype of TP53 codon 72 appears
to be an independent prognostic marker in breast cancer
patients.
Introduction
The TP53 tumor suppressor pathway is well-known to be cru-
cial for maintaining genomic integrity and preventing cells from
undergoing oncogenic transformation [1,2]. MDM2 plays a
key role in regulating the TP53 pathway by binding directly to
the p53 protein, inhibiting its activity and mediating degrada-
tion via the ubiquitination system [3]. p53 also positively regu-
lates MDM2 expression, thereby creating a negative feedback
loop [3]. Overexpression of MDM2 is observed both in epithe-
lial cells of transgenic mice with induced mammary carcino-
mas [4] and in multiple human tumors, including breast cancer
[5-7].
The TP53 codon 72 Arg>Pro (CGC to CCC) polymorphism
of exon 4 [8] (National Center for Biotechnology Information
single-nucleotide polymorphism (SNP) identification number
rs1042522) has been suggested to play a role in several dif-
ferent cancer types. These two variant protein forms may
behave differently, as the Arg/Arg genotype has been reported
to induce apoptosis more effectively than the Pro/Pro geno-
type [9,10], which may be due to enhanced mitochondrial
localization of p53 protein in cells with the Arg/Arg genotype
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[9]. In contrast, the Pro/Pro genotype appears to induce a
higher level of G1 arrest than the Arg/Arg genotype [11,12].
Patients with the Pro/Pro genotype of TP53 in breast cancers
have poorer survival than those with other genotypes [13]. Fur-
thermore, retention of the Arg allele of TP53 in tumor tissue of
Arg/Pro heterozygous breast cancer patients has been asso-
ciated with reduced disease-free and overall survival [14]. Tai-
wanese lung cancer patients and Israeli colorectal cancer
patients with the Pro/Pro genotype of TP53  also showed
poorer survival [15,16]. A recent study showed that breast
cancer patients with the Pro/Pro genotype were less sensitive
to chemotherapy than those with Arg/Arg or Arg/Pro geno-
types [17]. Similar results were reported in head and neck car-
cinoma [11]. On the other hand, estrogen receptor (ER)
positive patients possessing the Pro allele had better distant
recurrence-free survival when randomized to tamoxifen com-
pared to those who did not receive tamoxifen, while
homozygous Arg/Arg patients did not [18]. After the initial
report of a statistically significantly increased risk of breast
cancer in women homozygous for the Pro allele [19], numer-
ous studies examined a possible role of this TP53 polymor-
phism in breast cancer risk. Meta-analysis of nine studies has
recently shown that this TP53 polymorphism is not associated
with breast cancer risk [20].
A SNP in the promoter of the MDM2 gene, referred to as
SNP309 (a T→G change) (rs2279744), has been implicated
in earlier age of onset of Li-Fraumeni syndrome and sporadic
cancers [21]. The MDM2 SNP309 G/G homozygous geno-
type elevates MDM2 protein expression [21]. A recent study
showed that cells that harbor this genotype had a compro-
mised TP53 response pathway and formed transcriptionally
inactive p53-MDM2 complexes in response to stress [22]. The
G/G genotype was also associated with increased incidence
of esophageal squamous cell carcinoma [23]. Colorectal can-
cer patients who had both the SNP309 G allele and wild-type
TP53 were diagnosed at a younger age than those with the T/
T genotype and wild-type TP53 [24]. On the other hand, no
association was found between SNP309 status and breast
cancer incidence [25-27]. However, a recent study showed
that, in women whose breast cancers expressed high levels of
ER, those having the MDM2 SNP309 G/G genotype showed
earlier age of onset than those with the T/T genotype [28].
Another study showed that among patients with the T/T geno-
type, mutant status of TP53 and aberrant p53 protein expres-
sion were associated with poor survival, suggesting an
interaction between MDM2 SNP309 and tumor TP53 status
[25].
Here, we have examined germ-line DNA samples from 557
consecutive primary breast cancer patients to investigate the




Blood samples were obtained from a total of 557 consecutive
primary breast cancer patients at Nagoya City University Hos-
pital, Nagoya, Japan, between January 1983 and December
2003. Informed consent was obtained from all patients before
surgery. The histological grade was estimated according to
the Bloom and Richardson method proposed by Elston and
Ellis [29]. Treatment decisions were based on consensus rec-
ommendations at that time in Japan. After surgery, 77 patients
received no adjuvant therapy. A total of 137 patients received
adjuvant chemotherapy alone (64 received oral 5-fluorouracil
(5-FU), 41 were treated with a CMF (cyclophosphamide/
methotrexate/5-FU)-based regimen, 26 with an anthracycline-
based regimen, and 6 received other regimens). A total of 195
patients received adjuvant hormonal therapy alone (157
received tamoxifen, 28 tamoxifen plus luteinizing hormone-
releasing hormone (LH-RH) agonist, 5 were treated with LH-
RH alone, and 5 with aromatase inhibitor). A total of 144
patients received a combination of hormonal therapy and
chemotherapy. The adjuvant therapy received by four patients
could not be determined due to missing records. Patients
were followed postoperatively every three months for the first
five years, then annually. The median follow-up period was
61.7 months (range 3 to 258 months). Relapse data were
available in 497 of 557 patients examined: 105 (21.1%) expe-
rienced disease recurrence; 95 (19.1%) showed distant
relapse; and 58 (11.6%) had died. This protocol was
approved by the Institutional Review Board of Nagoya City
University Graduate School of Medical Sciences.
DNA extraction and genotyping
Genomic DNA was isolated from peripheral blood lym-
phocytes using a phenol-chloroform extraction method. Sam-
ples of genomic DNA were genotyped for TP53 codon 72 and
MDM2 SNP309 polymorphisms. Genotyping was performed
using TaqMan SNP genotyping assays. One TP53  probe
(CTGCTCCCCGCGTGGCCC) was labeled at the 5'-end
with VIC (Applied Biosystems' proprietary dye) and at the 3'-
end with TAMRA. The other (CTGCTCCCCCCGTGGCCC)
was labeled at the 5'-end with 6-carboxyfluorescein (FAM) and
at the 3'-end with TAMRA. The TP53 primers were: forward,
5'-ATGAAGCTCCCAGAATGC-3', and reverse, 5'-GCCG-
GTGTAGGAGCT-3'. One MDM2  probe (CGCTGCG-
GCGCGGGA) was labeled at the 5'-end with VIC and labeled
at the 3'-end with TAMRA. The other (CCGCTTCGGCGCG-
GGA) was labeled at the 5'-end with FAM and at the 3'-end
with TAMRA. The MDM2 primers used for genotyping and
sequencing were: forward, 5'-ATTTCGGACGGCTCTCGC-
3', and reverse, 5'-GCGCAGCGTTCACACTAGTG-3'. Real-
time TaqMan PCR and genotyping analyses were performed
on an Applied Biosystems 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA) according to the
manufacturer's standard PCR protocol. The results were ana-
lyzed on a 7500 real-time PCR system using the allelicAvailable online http://breast-cancer-research.com/content/9/3/R34
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discrimination assay program of Sequence Detection software
version 1.3.1 (Applied Biosystems).
DNA sequencing
DNA sequencing was performed to confirm the results of Taq-
Man SNP genotyping assays. The primers used for sequenc-
ing of TP53  were: forward, 5'-
CCCGGACGATATTGAACAATGG-3', and reverse, 5'-
CAGAATGCAAGAAGCCCAGAC-3'. As mentioned above,
the primers used for sequencing of MDM2 were the same as
those utilized in the TaqMan genotyping assays. The PCR
products were sequenced by an ABI PRISM 3100 Genetic
Analyzer and analyzed by ABI SeqScape Software version
2.1.1 (Applied Biosystems).
Immunohistochemical analysis for p53
Serial sections (4 μm) for p53 staining were prepared from
289 consecutive breast cancer tissue blocks from 1983 to
1999 at Nagoya City University Hospital [30]. A monoclonal
mouse antihuman p53 protein antibody (PAb1801; Novocas-
tra, Newcastle, UK) was used at a 1:50 dilution. Bound anti-
body was detected with a streptavidin-biotin system (SAB-PO
kit; Nichirei Co., Inc., Tokyo, Japan). Immunostaining was
scored after the entire slide had been evaluated by light micro-
scopy. The expression status of p53 was assessed according
to the estimated proportion of tumor cells displaying positive
nuclear staining. Scoring criteria for p53 protein expression
were as follows (in the form, proportion of nuclear staining =
score): none = 0, <1/10 = 1, 1/10 to 1/2 = 2, and >1/2 = 3.
Tumors with a score of 1 or greater were considered to be
positive for p53 protein accumulation.
Estrogen receptor measurement
Frozen tissue specimens were analyzed for ER by an enzyme
immunoassay using ER EIA 'Abbott' (Dinabot, Tokyo, Japan).
The cut-off ER level was less than 13 fmol/mg protein.
Statistical analyses
All molecular and immunohistochemical analyses were per-
formed blinded to clinical data. Statistical calculations were
done with StatView-J 5.0 software (SAS Institute Inc., Cary,
NC, USA). The relationship between the genotype frequency
of TP53 codon 72 or MDM2 SNP309 and clinicopathological
factors were assessed by χ2 and Fisher's exact probability
tests. Disease-free survival (DFS) curves were generated by
the Kaplan-Meier method and verified by the log-rank test.
Cox's proportional hazards regression analysis was used for
univariate and multivariate analyses of prognostic values. Dif-
ferences were considered significant when a P value < 0.05
was obtained.
Results
Distributions of TP53 and MDM2 polymorphisms
Each of the TP53 codon 72 genotypes (Arg/Arg, Arg/Pro, or
Pro/Pro) and MDM2 SNP309 genotypes (T/T, T/G, or G/G)
was clearly discriminated using TaqMan SNP genotyping
assays. The allelic discrimination data from these assays were
confirmed by direct sequencing of representative PCR prod-
ucts. We did not find an association between TP53 codon 72
or  MDM2  SNP309 genotypes and clinicopathological fea-
tures in our series (Tables 1 and 2).
TP53 and MDM2 genotypes and breast cancer survival
We investigated whether these SNPs were associated with
breast cancer survival. We found no association between
MDM2 SNP309 status and DFS, as shown in Figure 1a. In
contrast, the Pro/Pro genotype of TP53 codon 72 was signif-
icantly associated with poor DFS by Kaplan-Meier analysis, as
shown in Figure 1b (P = 0.049), and multivariate Cox's propor-
tional hazards regression analysis (P  = 0.047, risk ratio of
recurrence = 1.67, 95% confidence interval = 1.01 to 2.76)
(Table 3). Our data indicates that the Pro/Pro genotype of
TP53 codon 72 is an independent prognostic marker in breast
cancer. In this analysis, we combined the Arg/Arg
homozygous and the Arg/Pro heterozygous genotypes of
TP53 codon 72, because the survival curve of the patients
with the Arg/Arg genotype was similar to that of patients with
the Arg/Pro genotype (data not shown). When the analysis
was stratified by nodal status, no significant association
between TP53 codon 72 genotype and DFS was seen for
node-negative patients (P = 0.95; Figure 1c). In node-positive
patients, however, the Pro/Pro genotype of TP53 codon 72
was significantly associated with poor DFS (P = 0.004; Figure
1d). Only 85 (26%) of 321 node-negative patients had
received chemotherapy while 151 (76%) of 198 node-positive
patients had. Therefore, we analyzed the relationship between
breast cancer survival and this TP53 polymorphism in sub-
groups based on the type of adjuvant therapy.
TP53 and MDM2 genotypes and adjuvant systemic 
therapy
Previous in vitro studies showed that cells with the TP53
codon 72 Arg/Arg genotype induced apoptosis markedly bet-
ter than those with the Pro/Pro genotype [9,11]. A recent clin-
ical study also suggested that breast cancer patients with the
Pro/Pro genotype might be less sensitive to neoadjuvant
chemotherapy than those with the Arg/Arg or Arg/Pro geno-
type [17]. Therefore, we hypothesized that this polymorphism
might alter the sensitivity of tumors to adjuvant therapeutic
agents. We analyzed the association between TP53 codon 72
polymorphism and DFS under different types of adjuvant sys-
temic therapy. Our results show that, among patients who had
received adjuvant chemotherapy alone (n = 137), those with
the Pro/Pro genotype had poorer DFS than those with the
Arg/Arg or Arg/Pro genotype, according to a Kaplan-Meier
survival analysis (P = 0.009; Figure 2a). Similar results were
observed when the analysis was expanded to include all
patients receiving chemotherapy, with or without hormonal
therapy (n = 281, P = 0.007; Figure 2b). In contrast, TP53
codon 72 genotype was not associated with DFS amongBreast Cancer Research    Vol 9 No 3    Toyama et al.
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patients who had received adjuvant hormonal therapy without
chemotherapy (n = 195, P = 0.58; Figure 2c) nor among
those who had received no adjuvant systemic therapy (n = 77,
P = 0.24; Figure 2d).
A recent study proposed a model in which an estrogen-signal-
ing pathway allows the G-allele of MDM2 SNP309 to acceler-
ate breast cancer formation [28]. We hypothesized that this
allele might also alter the sensitivity of tumors to adjuvant hor-
monal therapy. We therefore examined the correlation
between  MDM2  SNP309 and prognosis in patients who
received adjuvant tamoxifen with or without LH-RH agonist.
Although the T/T genotype tended to be associated with bet-
ter DFS compared to other genotypes of SNP309 (Figure 2e),
this association did not achieve significance (P = 0.09), and
no statistically significant correlation was found between prog-
nosis and MDM2 SNP309 genotype.
Discussion
We demonstrate here that SNPs of TP53 codon 72 may have
an important role in breast cancer. We show that the Pro/Pro
genotype at codon 72 of TP53 was associated with poor DFS,
particularly in patients who received adjuvant chemotherapy
while MDM2 SNP309 was not associated with prognosis.
TP53 codon 72 encodes two distinct functional allelic forms:
arginine (Arg) or proline (Pro) [8]. Polymorphism at this codon
has been suggested to modulate TP53-dependent apoptosis
Table 1
Association between TP53 codon 72 status and clinicopathological characteristics
Total, n (percent) Arg/Arg, n (percent) Arg/Pro, n (percent) Arg/Arg +Arg/Pro, n (percent) Pro/Pro, n (percent) Pa
Patients 557 (100) 63 (11) 281 (51) 344 (62) 213 (38)
Age (median, year) (n = 557) 55 57 56 58
Tumor size (n = 557) 0.16
≤ 2 cm 202 (36) 17 (27) 99 (35) 116 (33) 86 (40)
2 cm to ≤ 5 cm 286 (51) 37 (59) 151 (54) 188 (55) 98 (46)
>5 cm 57 (10) 6 (9) 28 (10) 34 (10) 23 (11)
Unknown 12 (2) 3 (5) 3 (1) 6 (2) 6 (3)
Node status (n = 557) >0.99
Negative 321 (58) 34 (54) 167 (60) 201 (58) 120 (56)
Positive 198 (35) 25 (40) 99 (35) 124 (36) 74 (35)
Unknown 38 (7) 4 (6) 15 (5) 19 (6) 19 (9)
Histology (n = 557) 0.98
IDC 486 (87) 54 (86) 246 (87) 300 (87) 186 (87)
ILC 20 (4) 2 (3) 10 (4) 12 (4) 8 (4)
Others 51 (9) 7 (11) 25 (9) 32 (9) 19 (9)
ER status (n = 557) 0.13
Positive 344 (62) 33 (52) 171 (61) 204 (59) 140 (66)
Negative 181 (32) 25 (40) 95 (34) 120 (35) 61 (29)
Unknown 32 (6) 5 (8) 15 (5) 20 (6) 12 (5)
Grade (n = 289) 0.27
1 71 (24) 3 (9) 48 (32) 51 (28) 20 (19)
2 147 (51) 21 (62) 67 (45) 89 (48) 59 (56)
3 54 (19) 8 (23) 28 (19) 36 (19) 18 (17)
Unknown 17 (6) 2 (6) 7 (4) 9 (5) 8 (8)
p53 IHC (n = 289) >0.99
Positive 72 (25) 15 (44) 29 (19) 44 (24) 28 (27)
Negative 196 (68) 19 (56) 108 (72) 127 (69) 69 (66)
Unknown 21 (7) 0 (0) 13 (9) 13 (7) 8 (7)
aArg/Arg and Arg/Pro genotypes compared with Pro/Pro genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive 
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and modify sensitivity to chemotherapeutic agents
[9,11,12,17]. Recent studies reported that the Pro/Pro geno-
type of TP53 codon 72 was associated with poorer survival in
Finnish breast cancer patients [13], and suggested that
MDM2 SNP309 status is associated with p53 protein func-
tion [21,22]. These findings inspired us to investigate the
association of breast cancer prognosis with SNPs of TP53
codon 72 and MDM2 SNP309. We used the TaqMan SNP
genotyping assay, which is amenable to high-throughput gen-
otyping and avoids many problems of traditional genotyping
assays, such as PCR-restriction fragment length polymor-
phism [31]. Although the TaqMan assay is convenient and reli-
able, it is less accurate than direct sequencing. Therefore, we
analyzed our data carefully. Our results show that the Pro/Pro
genotype of TP53 was associated with poorer DFS in Japa-
nese breast cancers patients, thus supporting the Finnish
study mentioned above [13]. However, the authors of that
study did not address the question of why the Pro/Pro
genotype of TP53 adversely affected the prognosis of breast
cancer patients. Analysis of our entire set of 557 patients
showed a relationship between the TP53 Pro/Pro genotype
and DFS, but with a P value (0.047) at the borderline of signif-
Table 2
Association between MDM2 SNP309 status and clinicopathological characteristics
Total, n (percent) T/T, n (percent) T/G, n (percent) T/T + T/G, n (percent) G/G, n (percent) Pa
Patients 557 (100) 111 (20) 263 (47) 374 (67) 183 (33)
Age (median, year) (n = 557) 57 56 56 58
Tumor size (n = 557) 0.49
≤ 2 cm 202 (36) 49 (44) 88 (33) 137 (37) 65 (36)
2 cm to ≤ 5 cm 286 (51) 53 (48) 139 (53) 192 (51) 94 (51)
>5 cm 57 (10) 6 (5) 28 (11) 34 (9) 23 (12)
Unknown 12 (2) 3 (3) 8 (3) 11 (3) 1 (1)
Node status (n = 557) 0.63
Negative 321 (58) 59 (53) 159 (60) 218 (58) 103 (56)
Positive 198 (35) 42 (38) 88 (34) 130 (35) 68 (37)
Unknown 38 (7) 10 (9) 16 (6) 26 (7) 12 (7)
Histology (n = 557) 0.44
IDC 486 (87) 97 (87) 233 (89) 330 (88) 156 (85)
ILC 20 (4) 3 (3) 8 (3) 11 (3) 9 (5)
Others 51 (9) 11 (10) 22 (8) 33 (9) 18 (10)
ER status (n = 557) 0.14
Positive 344 (62) 68 (61) 153 (58) 221 (59) 123 (67)
Negative 181 (32) 33 (30) 95 (36) 128 (34) 53 (29)
Unknown 32 (6) 10 (9) 15 (6) 25 (7) 7 (4)
Grade (n = 289) 0.19
1 71 (24) 19 (31) 36 (26) 55 (27) 16 (18)
2 147 (51) 29 (47) 66 (47) 95 (47) 52 (60)
3 54 (19) 10 (16) 29 (21) 39 (19) 15 (17)
Unknown 17 (6) 4 (6) 9 (6) 13 (6) 4 (5)
p53 IHC (n = 289) >0.99
Positive 72 (25) 19 (31) 31 (22) 50 (25) 22 (25)
Negative 196 (68) 41 (66) 95 (68) 136 (67) 60 (69)
Unknown 21 (7) 2 (3) 14 (10) 16 (8) 5 (6)
aT/T + T/G genotypes versus G/G genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive 
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icance, leaving doubt as to whether the Pro/Pro genotype is
an independent risk factor for poor DFS.
We therefore attempted to identify subgroups in which the
effect of the TP53 codon 72 was more significant. A recent
study showed that breast cancer patients with the Pro/Pro
genotype demonstrated less sensitivity to a neoadjuvant
chemotherapy regimen that included 5-FU, cyclophospha-
mide, and the anthracycline derivative pirarubicin [17]. This
suggested that TP53  codon 72 polymorphism might be a
strong predictive marker for chemotherapy response in breast
cancer patients. Our data show that the Pro/Pro genotype was
associated with poor DFS in node-positive but not in node-
negative patients, and 76% of node-positive patients in our
series had received adjuvant chemotherapy while only 26% of
node-negative patients had.
Although lymph node status is an important factor in classical
staging of breast cancer based on histological/anatomical
markers, there is little evidence that breast cancers with lymph
node involvement are biologically different from those without
it [32-34]. We therefore considered that the apparent effect of
node status on the relationship between TP53 genotype and
node status was due to a correlation between codon 72 poly-
morphism and effect of adjuvant chemotherapy, since 76% of
node-positive patients in our series had received such therapy
while only 26% of node-negative patients had. We thus ana-
lyzed breast cancer survival with respect to this TP53 polymor-
phism and the type of adjuvant therapy administered. Our data
show that among patients who had received adjuvant chemo-
therapy, those with the Pro/Pro genotype of TP53 exhibited
poorer DFS. Our finding is also consistent with a previous
study of head and neck carcinoma showing that among
patients who had received chemo-radiotherapy, those with the
Pro/Pro genotype of TP53 showed poorer survival compared
to patients with other genotypes [11].
Moreover, in ovarian cancer patients who received adjuvant
cisplatinum/paclitaxel chemotherapy, the TP53 Pro allele was
associated with a poorer prognosis [35]. An in vitro study
Table 3
Uni- and mutivariate Cox's model (disease-free survival) of prognostic factors
Univariate Multivariate
Variables n P value P value RR of recurrence (95 percent CI)
TP53 codon 72 status 557
Arg/Arg or Arg/Pro 1.0 (referent)
Pro/Pro 0.049 0.047 1.67 (1.01 to 2.76)
MDM2 SNP309 status 557
T/T or T/G 1.0 (referent)
G/G 0.41 0.99 1.00 (0.57 to 1.75)
Tumor size 545
<2 cm 1.0 (referent)
≥2 cm 0.001 0.69 1.14 (0.61 to 2.12)
Lymph node 519
Negative 1.0 (referent)
Positive <0.0001 <0.0001 4.09 (2.35 to 7.12)
ER status 525
Positive 1.0 (referent)
Negative <0.0001 0.002 2.48 (1.40 to 4.39)
Grade 272
1 1.0 (referent)
2 or 3 0.009 0.29 1.50 (0.71 to 3.14)
p53 IHC status 268
Negative 1.0 (referent)
Positive 0.18 0.14 0.64 (0.35 to 1.16)
CI, confidence interval; ER, estrogen receptor; IHC, immunohistochemistry; RR, risk ratio.Available online http://breast-cancer-research.com/content/9/3/R34
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showed that anticancer agents such as doxorubicin, 5-FU, and
cisplatin induced a higher level of apoptosis in human H1299
cells expressing the Arg/Arg genotype of TP53 codon 72 than
in those expressing the Pro/Pro genotype [11]. In addition, in
a colony-survival assay, doxorubicin and cisplatin were more
cytotoxic to cells expressing the Arg variant than to those
expressing the Pro variant [11]. Our data are consistent with
this in vitro study. The results among patients receiving both
chemotherapy and hormonal therapy were similar to those
among patients who had received adjuvant chemotherapy
alone (data not shown), but no correlation was found between
TP53 polymorphism and DFS among the patients receiving
adjuvant hormonal therapy alone. Positive correlation between
TP53 polymorphism and DFS was observed among patients
receiving any chemotherapeutic agents. Since these com-
pounds are cytotoxic while hormonal therapeutic agents are
cytostatic, our results may reflect differential effects of TP53
polymorphism on different apoptotic pathways. Recently, ER
positive patients possessing the Pro allele of TP53 codon 72
have been reported to show better distant recurrence-free sur-
vival when randomized to tamoxifen compared to those not
receiving tamoxifen [18]. That report suggested that the Pro
allele of TP53 codon 72 might be a predictor of tamoxifen
response [18], although the authors did not present a Kaplan-
Meier analysis of DFS by TP53 codon 72 genotype among
patients receiving tamoxifen. We did not find any correlation
between the genotype of TP53 codon 72 and prognosis in
patients receiving tamoxifen alone (data not shown).
Neither did we find any statistically significant association
between MDM2 SNP309 and survival in any subgroups or in
the total population, although we did observe a non-significant
tendency toward better DFS with the T/T genotype in patients
who received adjuvant tamoxifen with or without LH-RH ana-
log. Bond et al. [28] proposed a model in which an estrogen-
signaling pathway allows the G-allele of MDM2 SNP309 to
accelerate breast cancer formation. This allele might also alter
the efficacy of tamoxifen, although the mechanism is unclear.
A recent report showed that the G/G genotype of MDM2
SNP309 was associated with poor prognosis, as well as
TP53 mutations and p53 protein immunopositivity, in gastric
carcinoma [36]. TP53 alteration is correlated with shortened
survival of patients with gastric carcinoma [37,38]. This sug-
gests that the G/G genotype of MDM2 SNP309 might, there-
fore, be predictive of poor survival in gastric carcinoma
patients. Many reports demonstrate that TP53 mutations con-
Figure 1
Kaplan-Meier survival curves of breast cancer patients Kaplan-Meier survival curves of breast cancer patients. Disease-free survival (DFS) among patients categorized by (a) MDM2 SNP309 status and 
(b) TP53 codon 72 status. DFS in patients (c) without axillary lymph node involvement and (d) with lymph node metastasis according to their TP53 
codon 72 status. NS, not significant.Breast Cancer Research    Vol 9 No 3    Toyama et al.
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fer a worse overall and disease-free survival in breast cancer
patients [39,40], while the prognostic value of p53 protein
accumulation has not been consistently demonstrated
[41,42]. Although TP53 mutation status was not available in
our series, we analyzed the correlation between MDM2
SNP309 and p53-immunopositivity, but did not find any asso-
ciation between them.
In previous reports, the frequency of the Pro/Pro genotype of
TP53  codon 72 was about 7% to 30%
[13,15,17,18,23,43,44], although 39.1% of patients with sig-
net ring cell gastric carcinomas and 37.7% of female patients
with lung carcinomas had the Pro/Pro genotype in subgroup
analyses [15,44]. The reported frequency of the G/G geno-
type of MDM2 SNP309 is about 10% to 30% [23-28,36,43].
We found that 38% of patients had the Pro/Pro genotype of
TP53 codon 72 and 33% had the G/G genotype of MDM2
Figure 2
The effect of adjuvant systemic therapy on prognostic impact of polymorphisms The effect of adjuvant systemic therapy on prognostic impact of polymorphisms. (a) TP53 codon 72 and adjuvant chemotherapy alone (n = 137); 
(b) TP53 codon 72 and adjuvant chemotherapy with or without hormonal therapy (n = 281); (c) TP53 codon 72 and adjuvant hormonal therapy 
alone (n = 195); (d) TP53 codon 72 and no adjuvant systemic therapy (n = 77); (e) MDM2 SNP309 and adjuvant tamoxifen with or without lutein-
izing hormone-releasing hormone analog (n = 185). DFS, disease-free survival.Available online http://breast-cancer-research.com/content/9/3/R34
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SNP309. Therefore, the allelic discrimination data from Taq-
Man SNP genotyping assays were confirmed by direct
sequencing of representative PCR products.
One of the goals of translational cancer research is to identify
molecular predictors of chemotherapy treatment. Molecular
genetic determinants of treatment outcome are important to
facilitate identification of patients most likely to benefit from
chemotherapy. The present results suggest that the SNP of
TP53 codon 72 is a potentially useful marker. However, this is
a retrospective pilot study. Further work will be needed to ver-
ify the effect of this SNP in breast cancer.
Conclusion
The genotypes of TP53 codon 72 and MDM2 SNP309 were
defined among 557 primary Japanese breast cancer patients.
Our data show that the Pro/Pro genotype of TP53 codon 72
appears to be an independent prognostic marker in breast
cancer patients.
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